97106 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
SINGLE DOMAIN ANTIBODIES TARGETING HPV E6/E7 ONCOGENIC PEPTIDE/MHC COMPLEXES
#2BK VIRUS NEUTRALIZING ANTIBODIES
#3BK VIRUS NEUTRALIZING ANTIBODIES
#4MONOCLONAL ANTIBODIES AGAINST JC VIRUS
#5HPV Proteins, Antibodies, and Uses in Managing Abnormal Epithelial Cell Growth
#6NEUTRALIZING MONOCLONAL ANTIBODIES TO BK VIRUS
#7METHODS FOR OBTAINING ANTIBODY MOLECULES BINDING TO A PEPTIDE-MHC INTERFACE
#8ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
#9POLYOMAVIRUS NEUTRALIZING ANTIBODIES
#10Modified Cytotoxic T Cells and Methods of Use Thereof
#11MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF
#12ANTI-HPV ANTIBODIES AND USES THEREOF
#13ANTI-BK VIRUS ANTIBODY MOLECULES
#14ENGINEERING BIOLOGICS TO HPV ONCOPROTEINS
#15MUTATED FERRITIN PROTEIN
#16VIRUS-LIKE PARTICLE CONJUGATES FOR DIAGNOSIS AND TREATMENT OF TUMORS
#17ANTIBODIES, FRAGMENTS OR DERIVATIVES SPECIFICALLY BINDING TO A PROTEIN ANTIGEN CAPABLE OF BINDING TO NUCLEIC ACIDS AND USES OF SAME
#18ANTI-HPV6 L1 PROTEIN ANTIBODY AND DETECTION METHOD USING THE ANTIBODY
#19ANTI-BK VIRUS ANTIBODY MOLECULES
#20T CELLS AGAINST HUMAN PAPILLOMAVIRUS
#21Polyomavirus neutralizing antibodies
#22Canine parvovirus nanobody CPV-VHH-E3 and application thereof
#23T CELLS AND CHIMERIC STIMULATING RECEPTORS AND USES THEREOF
#24BINDING PROTEINS RECOGNIZING HPV16 E7 ANTIGEN AND USES THEREOF
#25Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof
#26T CELL RECEPTORS AND ENGINEERED CELLS EXPRESSING SAME
#27COMPOSITIONS AND METHODS FOR TREATING MERKEL CELL CARCINOMA (MCC) USING HLA CLASS I SPECIFIC EPITOPES
#28DOSING OF POLYOMAVIRUS NEUTRALIZING ANTIBODIES
#29Anti-BK virus antibody molecules
#30Bispecific Molecules That Are Immunoreactive With Immune Effector Cells That Express An Activating Receptor And An Antigen Expressed By A Cell Infected By A Virus And Uses Thereof
#31POLYOMAVIRUS NEUTRALIZING ANTIBODIES
#32NEW ANTIBODY TARGETING THE VP-1 PROTEIN, FRAGMENTS THEREOF, AND USES OF SAME FOR DETECTING INFECTION WITH THE BK POLYOMAVIRUS
#33Virus-like particle conjugates for diagnosis and treatment of tumors
#34Polyomavirus neutralizing antibodies
#35MONOCLONAL ANTIBODIES AGAINST JC VIRUS
#36Virus-like particle conjugates for diagnosis and treatment of tumors
#37Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof
#38VIRUS-LIKE PARTICLE CONJUGATES FOR DIAGNOSIS AND TREATMENT OF TUMORS
#39HPV-SPECIFIC BINDING MOLECULES
#40CELL PENETRATING CONJUGATES AND METHODS OF USE THEREOF
#41MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF
#42ABERRANT CELL-RESTRICTED IMMUNOGLOBULINS PROVIDED WITH A TOXIC MOIETY
#43Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof
#44Serologic test for therapy control of HPV16 positive carcinoma
#45HPV Proteins, Antibodies, and Uses in Managing Abnormal Epithelial Cell Growth
#46Polyomavirus neutralizing antibodies
#47Polyomavirus neutralizing antibodies
#48Virus-like particle conjugates for diagnosis and treatment of tumors
#49POLYPEPTIDE VACCINE
#50HUMAN PAPILLOMA VIRUS DETECTION
#51Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
#52Compositions containing anti-HIV ostrich antibodies
#53NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME FOR THE TREATMENT OF CANCER AND INFECTIOUS DISEASES
#54T cell receptors and engineered cells expressing same
#55HPV-specific binding molecules
#56HPV particles and uses thereof
#57Serologic test for therapy control of HPV16 positive carcinoma
#58Treatment and prevention of anal conditions
#59Virus-like particle conjugates for diagnosis and treatment of tumors
#60Polyomavirus neutralizing antibodies
#61High avidity HPV T-cell receptors
#62Antibody and antibody-containing composition
#63Polyomavirus neutralizing antibodies
#64Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof
#65TARGETED CANCER THERAPY
#66Method for development of monoclonal antibodies
#67IMMUNOLOGICAL TEST FOR THE DETECTION OF E7 ONCOPROTEINS IN BIOLOGICAL SAMPLES
#68Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof
#69ABERRANT CELL-RESTRICTED IMMUNOGLOBULINS PROVIDED WITH A TOXIC MOIETY
#70Polyomavirus neutralizing antibodies
#71Antibody and antibody-containing composition
#72Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
#73HPV particles and uses thereof
#74Cervical cancer-related HPV E7 protein monoclonal antibody and use thereof
#75Polyomavirus neutralizing antibodies
#76Antibody and antibody-containing composition
#77Cell penetrating conjugates and methods of use thereof
#78Compositions and methods for inhibiting JC virus (JCV)
#79IMMUNOGENIC POLYPEPTIDES COMPRISING A SCAFFOLD POLYPEPTIDE AND A L2 POLYPEPTIDE OR A FRAGMENT THEREOF
#80Anti-HPV E7 antibodies
#81Virus-like particle conjugates for diagnosis and treatment of tumors
#82Fine epitope peptide capable of inducing cross-reactive antibodies among homologous proteins in human papilloma virus E6 protein
#83Monoclonal antibody recognizing human papillomavirus (HPV) L2 protein and method for measuring HPV-neutralizing antibody titer using the same
#84Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same
#85Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
#86Antibody molecules
#87Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof
#88Vaccines against HPV
#89Polypeptide vaccine
#90Human monoclonal antibody against the VP1 protein of JC virus
#91Polyclonal bispecific antibody compositions and method of use
#92ANTIBODIES SPECIFIC TO E6 PROTEINS OF HPV AND USE THEREOF
#93In situ detection of early stages and late stages HPV infection
#94Antibodies for oncogenic strains of HPV and methods of their use
#95Aberrant cell-restricted immunoglobulins provided with a toxic moiety
#96VACCINES AGAINST HPV
#97JCV neutralizing antibodies
#98JCV neutralizing antibodies
#99Antibodies Against E7 Protein of Human Papilloma Virus (HPV)
#100ANTIBODY AND ANTIBODY-CONTAINING COMPOSITION
#101Antibody molecules
#102Monoclonal antibody recognizing human papillomavirus (HPV) L2 protein and method for measuring HPV-neutralizing antibody titer using the same
#103COMPOSITIONS AND METHODS RELATING TO MOUSE PAPILLOMA VIRUS
#104Minimal motifs of linear B-cell epitopes in L1 protein from human papillomavirus type 58 and their applications
#105Anti-HPV E7 antibodies
#106DETECTION OF EARLY STAGES AND LATE STAGES HPV INFECTION
#107Polyclonal bispecific antibody compositions and method of use
#108HPV particles and uses thereof
#109Antibodies For Oncogenic Strains Of HPV And Methods Of Their Use
#110ANTIBODIES SPECIFIC TO E6 PROTEINS OF HPV AND USE THEREOF
#111Viral vectors encoding multiple highly homologus non-viral polypeptides and the use of same
#112METHODS OF DIAGNOSING CERVICAL CANCER
#113Immunogenic polypeptides comprising a scaffold polypeptide and a L2 polypeptide or a fragment thereof
#114USE OF RNA TRANS-SPLICING FOR ANTIBODY GENE TRANSFER AND ANTIBODY POLYPEPTIDE PRODUCTION
#115Methods to diagnose and immunize against the virus causing human Merkel cell carcinoma
#116METHODS AND COMPOSITIONS FOR THE INHIBITION OF VIRAL INFECTION BY TARGETING INTRACELLULAR TRAFFICKING
#117Antibodies for oncogenic strains of HPV and methods of their use
#118Detection of early stages and late stages HPV infection
#119IN SITU detection of early stages and late stages HPV infection
#120Monoclonal antibodies against HPV proteins
#121In situ detection of early stages and late stages HPV infection
#122Advanced cervical cell screening methods
#123Antibodies for oncogenic strains of HPV and methods of their use
#124Antibody inhibiting infection of papillomavirus
#125Methods Kits and Compositions for the Developement and Use of Monoclonal Antibodies Specific to Anbtigens of Low Immunogenicity
#126Virus-like particles for the induction of autoantibodies
#127Methods of diagnosing cervical cancer
#128Combination of anti-hpv-16 and 18 antibodies and uses thereof
#129Systems of diagnosing cervical cancer
#130Antigens
#131Site-specific immunization in order to establish antibodies with specificity for the E7 oncoprotein of high-risk HPV's
#132Composition
#133Methods and compositions for treatment of viral lnfection
#134Virus-like particles for the induction of autoantibodies
#135Use of RNA trans-splicing for antibody gene transfer and antibody polypeptide production
#136Use of immunogenic immunosuppressive and/or angiogenic proteins which have been rendered inactive, process for their preparation and pharmaceutical or vaccinal uses
#137Anti-hpv-16 e7 antibodies and their use
#138Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
#139Methods of diagnosing cervical cancer
#140Antibodies for oncogenic strains of HPV and methods of their use
#141Production and applications for polyvalent vaccines against diseases caused by papilloma viruses
#142Polyvalent vaccine against diseases caused by papilloma viruses, method for the production and the use thereof